# Joydeep Ghosh

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/joydeep-ghosh/

## Facts

| Field | Value |
| --- | --- |
| Citations | 446 |
| Field | Ovarian cancer diagnosis and treatment |
| h-index | 11 |
| i10-index | 12 |
| Last Known Institution | Apollo Hospitals |
| OpenAlex ID | https://openalex.org/A5101570814 |
| ORCID iD | 0000-0002-5156-2412 |
| Works | 138 |

## Researcher papers

- [Perspective of Oncology Patients During COVID-19 Pandemic: A Prospective Observational Study From India](https://scholariq.org/papers/perspective-of-oncology-patients-during-covid-19-pandemic-a-prospective/)
- [Resource requirements and reduction in cardiac mortality from deep inspiration breath hold (DIBH) radiation therapy for left sided breast cancer patients: A prospective service development analysis](https://scholariq.org/papers/resource-requirements-and-reduction-in-cardiac-mortality-from-deep-inspiration/)
- [Maintenance therapy with a poly(ADP-ribose) polymerase inhibitor in patients with newly diagnosed advanced epithelial ovarian cancer: individual patient data and trial-level meta-analysis](https://scholariq.org/papers/maintenance-therapy-with-a-poly-adp-ribose-polymerase-inhibitor-in-patients-with/)
- [Isolated and Significant Left Main Coronary Artery Disease: Demographics, Hemodynamics and Angiographic Features](https://scholariq.org/papers/isolated-and-significant-left-main-coronary-artery-disease-demographics/)
- [Real world experience of treatment and outcome in ALK-rearranged metastatic nonsmall cell lung cancer: A multicenter study from India](https://scholariq.org/papers/real-world-experience-of-treatment-and-outcome-in-alk-rearranged-metastatic/)
- [Neoadjuvant imatinib: longer the better, need to modify risk stratification for adjuvant imatinib](https://scholariq.org/papers/neoadjuvant-imatinib-longer-the-better-need-to-modify-risk-stratification-for/)
- [Advisory for cancer patients during the COVIDpandemic](https://scholariq.org/papers/advisory-for-cancer-patients-during-the-covidpandemic/)
- [PDL1 expression and its correlation with outcomes in non-metastatic triple-negative breast cancer (TNBC)](https://scholariq.org/papers/pdl1-expression-and-its-correlation-with-outcomes-in-non-metastatic-triple/)
- [Patterns of recurrence in triple negative breast cancer patients (automated IHC) : An Indian Tertiary Care Center data.](https://scholariq.org/papers/patterns-of-recurrence-in-triple-negative-breast-cancer-patients-automated-ihc/)
- [Metronomic therapy in metastatic castrate-resistant prostate cancer: Experience from a tertiary cancer care center](https://scholariq.org/papers/metronomic-therapy-in-metastatic-castrate-resistant-prostate-cancer-experience/)
- [1339P Real-world experience of dacomitinib in mEGFR Advanced NSCLC: A single centre experience](https://scholariq.org/papers/1339p-real-world-experience-of-dacomitinib-in-megfr-advanced-nsclc-a-single/)

## Researcher topics

- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Cancer Diagnosis and Treatment](https://scholariq.org/topics/cancer-diagnosis-and-treatment/)

## Researcher university

- [Apollo Hospitals](https://scholariq.org/institutions/apollo-hospitals/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.